Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Patient recruitment & retention services
A large biopharmaceutical company with a Phase III trial enrolling 430 advanced Gastric Cancer patients contracted ICON to
support patient enrollment.
support patient enrollment.
In-Home Services: Patient centric practices
Accellacare was contracted by a large pharma organisation to recruit and provide In-Home Services to paediatric patients with autism.
Agile operations drive enrollment in COVID-19 treatment studies
ICON’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.
High-performing sites during COVID-19 in Women’s Health
A biotechnology company, dedicated to transforming Women’s Health, was running a phase 3 study in the treatment of moderate-to-severe vasomotor symptoms in postmenopausal women with a global enrollment target of 1,200 patients.
Beating patient recruitment target with enhanced patient experience
Accellacare was awarded an osteoarthritis study by a large biotech organisation. The study required recruitment of 1200+ patients across 20+ sites and four countries.
Overcoming the challenges of COVID-19 clinical trial conditions
A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=jGYL6rEb "Clinical research staff at work"){kind=icon}
High performing sites in cardiovascular study
Four studies were awarded by a pharma organisation over a period of less than two years, with overlapping
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.
start-up through close out timelines. Milestone expectations were aggressive, requiring an innovative approach and rapid start-up.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=2_t1WsJX "Accellacare staff providing care"){kind=icon}
Exceeding expectations in a c. diff vaccine study
Five Accellacare sites were selected to participate in a clostridium difficile (c. diff) vaccine study being conducted
by a large pharma sponsor and ICON.
by a large pharma sponsor and ICON.
Digital solutions to reduce risk potential for six-study dermatology programme
A large pharma company conducted an extensive atopic dermatitis program consisting of six studies with complex protocols and up to 537 active sites per study. The sponsor contacted ICON to implement a centralised digital solution to better manage this massive study and reduce risk potential.
Digital solutions for an evolving COVID-19 environment
One of the top five pharmaceutical companies in the world selected ICON to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.
Optimising biosimilar development
ICON’s proactivity in risk mitigation, commitment to the study, project planning and communication contributed significantly to the ultimate success of the study.
CRF design for a cell-therapy, immuno-oncology study
ICON developed flexible, cost-effective CRF designs for a cell therapy immuno-oncology study, harmonising RECIST and iRECIST criteria while addressing re-treatment requirements and supporting sponsors in meeting study timelines.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.